Special Drug Use Investigation of Xarelto for VTE

Trial Profile

Special Drug Use Investigation of Xarelto for VTE

Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Venous thromboembolism
  • Focus Adverse reactions
  • Acronyms JPMS-XAR-VTE
  • Sponsors Bayer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 29 Aug 2016 Planned End Date changed from 1 Mar 2019 to 1 Jan 2020.
    • 17 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top